Clinical trials of a preventative vaccine for the Ebola virus made by British
pharma company GlaxoSmithKline may begin next month and made available
by 2015 , the World Health Organization said on Saturday.
“ We are targeting September for the start of clinical trials , first in the
United States and certainly in African countries, since that ’s where we
have the cases, ” Jean -Marie Okwo Bele , the WHO’ s head of vaccines and
immunisation , told French radio.
He said he was optimistic about making the vaccine commercially available .
“ We think that if we start in September , we could already have results by
the end of the year .
“ And since this is an emergency, we can put emergency procedures in place
… so that we can have a vaccine available by 2015 . ”
There is currently no available cure or vaccine for Ebola , a virus that
causes severe fever and, in the worst cases, unstoppable bleeding .
It has claimed close to 1 , 000 lives in the latest epidemic to spread across
west Africa this year. Fatality rates can approach 90 percent , although the
latest outbreak has killed around 55 to 60 percent of those infected.
Several vaccines are being tested , and a treatment made by San Diego -
based Mapp Biopharmaceutical , ZMapp , has shown promising results on
monkeys and may have been effective in treating two Americans recently
infected in Africa .

I knew this company can handle it

this is good news just hope it get here quicker